Prevalence of sexual dysfunction after breast cancer compared to controls, a study from CONSTANCES cohort

Mangiardi-Veltin, Manon; Mullaert, Jimmy; Cœuret-Pellicer, Mireille; Goldberg, Marcel; Zins, Marie; Rouzier, Roman; Héquet, Delphine; Bonneau, Claire

doi:10.1007/s11764-023-01407-z

Cited by 2 publications

(1 citation statement)

References 36 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, efforts to detect sexual disorders in BC survivors and offer quality support must be pursued. 30 …”

Section: Discussionmentioning

confidence: 99%

Assessment of sexual function in postmenopausal breast cancer survivors

Vitorino,

Omodei,

de Souza

et al. 2024

Sexual Medicine

View full text Add to dashboard Cite

Background Breast cancer (BC) is considered a risk factor for sexual dysfunction, which may be associated with the diagnosis itself or with oncological treatments. However, sexual dysfunction often remains underdiagnosed and unaddressed among BC survivors. Aim The study sought to evaluate the sexual function of postmenopausal BC survivors compared with postmenopausal women without BC. Methods This case-control study included 178 postmenopausal BC survivors (stages I-III), 45 to 70 years of age, with amenorrhea for ≥12 months and sexually active. They were compared with 178 women without BC, matched (±2 years) for age and time since menopause in a 1:1 ratio. Sexual function was evaluated using the Female Sexual Function Index (FSFI), which consists of 6 domains (desire, arousal, lubrication, orgasm, satisfaction, and pain), with a total score ≤26.5 indicating risk of sexual dysfunction. Statistical analysis included Student’s t test, chi-square test, and logistic regression (odds ratio [OR]). Outcomes Evaluation of sexual function in postmenopausal women treated for BC. Results Postmenopausal BC survivors showed poorer sexual function in the desire domain (P = .002). No significant differences were observed between groups in the other FSFI domains and total score (P > .05). Postmenopausal BC survivors had a higher prevalence of risk of sexual dysfunction (64.6% with a total score ≤26.5) compared with the control group (51.6%) (P = .010). Adjusted risk analysis for age and time since menopause revealed a higher risk of sexual dysfunction in BC survivors compared with women without cancer (OR, 1.98; 95% confidence interval, 1.29-2.96; P = .007). Among BC survivors, the use of hormone therapy was associated with a higher risk of sexual dysfunction (OR, 3.46; 95% confidence interval, 1.59-7.51; P = .002). Clinical Implications Postmenopausal BC survivors should be regularly assessed before and throughout treatment to enable the early detection and diagnosis of sexual dysfunction. Strength and Limitations The main strength is that this study might contribute to a better understanding of sexual function in postmenopausal BC survivors compared with women without BC. The main limitation is that while the FSFI is a valid and reliable tool for the evaluation of female sexual function, it does not allow a comprehensive diagnosis of sexual dysfunction, as it is not applicable to partners. Conclusion Compared with postmenopausal women without BC, postmenopausal BC survivors face a higher risk of sexual dysfunction, especially when treated with adjuvant hormone therapy.

show abstract

“…Therefore, efforts to detect sexual disorders in BC survivors and offer quality support must be pursued. 30 …”

Section: Discussionmentioning

confidence: 99%